Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Why Monsanto (MON) Is A Must-Add Stock To Your Portfolio

Published 06/16/2017, 02:58 AM
Updated 07/09/2023, 06:31 AM

On Jun 16, we issued an updated research report on premium agricultural chemicals firm, Monsanto Company (NYSE:MON) .

Over the last three months, Monsanto’s shares yielded a return of 4.35%, outperforming 2.51% growth recorded by the Zacks classified Agriculture/Products industry.

Notably, the attractiveness of this stock as a current investment choice is supported by its favorable Value Growth Momentum Style Score ‘B’.

Reasons for the Solid Run

Increasing global population has been boosting demand for crop-yield enhancing products offered by Monsanto. Sales of the company’s Roundup Ready 2 Xtend Soybeans, and premium weed and insect control solutions are anticipated to shoot up in the quarters ahead.

Sturdy sales, favorable product pricing and crop acreage area expansion would likely help in augmenting Monsanto’s profitability in the quarters ahead. Notably, the company currently estimates to accrue adjusted earnings (ongoing basis) at the high end of the $4.50–$4.90 per share range, in fiscal 2017.

Monsanto is fortifying its Climate FieldView platform, as well as the existing seed and trait solutions’ portfolio with numerous innovation investments. For instance, the company noted that it has completed the initial phase of its planned $400 million Chesterfield research & development site expansion.

The site, which is likely to commence operations by the end of fiscal 2017, is anticipated to enhance Monsanto’s technological expertise. Additionally, commercialization of the Nemastrike technology (produces non-imitable nematode control solutions) is projected to secure sturdy market response from calendar year 2018.

Monsanto accepted Bayer AG’s (OTC:BAYRY) buyout offer worth $66 billion, inclusive of debt, in Sep 2016. Both the companies estimate to close the deal by the fall of calendar year 2017. Monsanto believes that this deal would unlock a tranche of growth opportunities for its business. Along with Bayer, this Zacks Rank #2 (Buy) company intends to develop advanced integrated optimized solutions for cultivators and cater new offerings in the market, which would be highly beneficial for farmers.

Over the last 60 days, the Zacks Consensus Estimate for the stock has been revised upward for both fiscal 2017 and 2018, indicating positive market sentiments.

Other Stocks to Consider

Some other top-ranked stocks in the industry are listed below:

BASF SE (DE:BASFN) (OTC:BASFY) generated an average positive earnings surprise of 3.02% over the trailing four quarters and currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Chemours Company (NYSE:CC) has an average positive earnings surprise of 39.82% for the last four quarters and boasts a Zacks Rank #1 at present.

3 Top Picks to Ride the Hottest Tech Trend

Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...

Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>



Bayer AG (DE:BAYGN) (BAYRY): Free Stock Analysis Report

BASF SE (BASFY): Free Stock Analysis Report

Chemours Company (The) (CC): Free Stock Analysis Report

Monsanto Company (MON): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

I don't like Monsanto company. Their first product made was agent orange. They products are detrimental to vitality of human life.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.